Hypothesis: The potential therapeutic role of nicorandil in COVID-19

Hend Ashour, Mohamed H Elsayed, Soha Elmorsy, Inas A Harb, Hend Ashour, Mohamed H Elsayed, Soha Elmorsy, Inas A Harb

Abstract

At present, there is yet no specific antiviral treatment or immunization against the newly identified human severe acute respiratory syndrome virus (SARS-CoV2) that results in a rapidly progressive pandemic coronavirus disease 2019 (COVID-19). We believe in a crucial need for a clinical strategy to counteract this viral pandemic based on the known pathogenesis throughout the disease course. Evidence suggests that exaggerated patient's inflammatory response and oxidative stress are likely to aggravate the disease pathology. The resulting endothelial dysfunction further induces fibrosis and coagulopathy. These disturbances can generate severe acute respiratory distress syndrome (ARDS) that can progress into respiratory and circulatory failure. Nicorandil is an anti-anginal vasodilator drug acts by increasing nitric oxide bioavailability and opening of the KATP channel. Recently, nicorandil has been recognized to possess multiple protective effects against tissue injury. Here, we address a possible modulatory role of nicorandil against COVID-19 pathogenesis. We hypothesise nicorandil would be an effective form of adjuvant therapy against COVID-19.

Keywords: COVID-19; anti-coagulation; anti-fibrosis; anti-inflammatory; anti-oxidative; nicorandil.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

© 2020 John Wiley & Sons Australia, Ltd.

References

    1. Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID‐19). Intens Care Med [Internet]. 2020;46(5):854‐887. Available from
    1. Huang C, Wang Y, Li X, Ren L, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497–506. 10.1016/s0140-6736(20)30183-5
    1. Organization WH .COVID‐19 CORONAVIRUS PANDEMIC [Internet]. Vol. 3, The Journal of Health Technology Assessment. 2020. Available from:
    1. Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol [Internet]. 2004;203(2):631‐637. Available from:
    1. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin‐converting enzyme 2 (ACE2) as a SARS‐CoV‐2 receptor: molecular mechanisms and potential therapeutic target. Intens Care Med [Internet]. 2020;46(4):586‐590. Available from
    1. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol [Internet]. 1989;63(21):J18‐24. Available from
    1. Cheung CY, Poon LLM, Ng IHY, et al. Cytokine responses in severe acute respiratory syndrome Coronavirus‐infected macrophages in vitro: possible relevance to pathogenesis. J Virol. 2005;79(12):7819‐7826.
    1. Liu Y, Ma S, Wang X, et al. The role of β2 integrin associated heparin‐binding protein release in ARDS. Life Sci [Internet]. 2018;203:92‐98. Available from
    1. Veerdonk FL, Netea MG, Deuren M, Meer JWM, Mast Q, Brüggemann RJ, et al. Kinins and cytokines in COVID‐19: a comprehensive pathophysiological approach. 2020. 10.20944/preprints202004.0023.v1
    1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID‐19) outbreak. J Autoimmun [Internet]. 2020;109:102433. Available from
    1. Luo W, Yu H, Jizhou Gou XL, Sun Y, Li J, Liu L.Clinical Pathology of Critical Patient with Novel Coronavirus Pneumonia (COVID‐19) : First Case of the Whole Lung Biopsy. 2020. p. Preprint.
    1. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID‐19 associated with acute respiratory distress syndrome. Lancet Respir Med [Internet]. 2020;8(4):420‐422. Available from
    1. Solaimanzadeh I. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID‐19). Cureus [Internet]. 2020;12(3):e7343.
    1. Zhang H, Downey GP, Suter PM, Slutsky AS, Ranieri VM. Conventional mechanical ventilation is associated with bronchoalveolar lavage‐induced activation of polymorphonuclear leukocytes. Anesthesiology [Internet]. 2002;97(6):1426‐1433. Available from
    1. Sarma JV, Ward PA. Oxidants and Redox Signaling in Acute Lung Injury. In: Terjung R, eds. Comprehensive Physiology, Vol. 3. Hoboken, NJ: John Wiley & Sons, Inc.; 2011:1365‐1381. Available from: 10.1002/cphy.c100068
    1. He M, Shi W, Yu M, et al. Nicorandil Attenuates LPS‐induced acute lung injury by pulmonary endothelial cell protection via NF‐ κ B and MAPK pathways. Oxid Med Cell Longev [Internet]. 2019;10(2019):1‐13. Available from
    1. Wang H, Zuo X, Wang Q, et al. Nicorandil inhibits hypoxia‐induced apoptosis in human pulmonary artery endothelial cells through activation of mitoKATP and regulation of eNOS and the NF‐κB pathway. Int J Mol Med [Internet]. 2013;32(1):187‐194. Available from
    1. Pieper GM, Gross GJ. Anti‐free‐radical and neutrophil‐modulating properties of the nitrovasodilator, nicorandil. Cardiovasc Drugs Ther [Internet]. 1992;6(3):225‐232. Available from
    1. Mano T, Shinohara R, Nagasaka A, et al. Scavenging effect of nicorandil on free radicals and lipid peroxide in streptozotocin‐induced diabetic rats. Metabolism [Internet]. 2000;49(4):427‐431. Available from
    1. El‐Kashef DH. Nicorandil ameliorates pulmonary inflammation and fibrosis in a rat model of silicosis. Int Immunopharmacol [Internet]. 2018;64:289‐297. Available from
    1. Wang C, Ke H, Xu X, Chen J, Sun D, Ji F. Protective effect of nicorandil on collapse‐induced lung injury in rabbits by inhibiting apoptosis. Int J Mol Med [Internet]. 2019;6(44):725‐736. Available from
    1. Abe K, Horiguchi T, Enzan K, Masaki Y, Nishikawa T, Kimura T. Nicorandil, a KATP Channel Opener, Attenuates Ischemia‐Reperfusion Injury in Isolated Rat Lungs. Lung [Internet]. 2020;198(2):315‐321. Available from
    1. Wajima Z, Yoshikawa T, Ogura A, et al. Intravenous nicorandil prevents thiamylal‐fentanyl–induced bronchoconstriction in humans*. Crit Care Med [Internet]. 2003;31(2):485‐490. Available from
    1. Scatena R, Bottoni P, Martorana GE, Giardina B. Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential. Expert Opin Investig Drugs [Internet]. 2005;14(7):835‐846. Available from
    1. Knox AJ, Tattersfield AE. Airway smooth muscle relaxation. Thorax [Internet]. 1995;50(8):894‐901. Available from
    1. Pelaia G, Gallelli L, Vatrella A, et al. Potential role of potassium channel openers in the treatment of asthma and chronic obstructive pulmonary disease. Life Sci [Internet]. 2002;70(9):977‐990. Available from
    1. Das K, Lee E, Singh R, et al. Follow‐up chest radiographic findings in patients with MERS‐CoV after recovery. Indian J Radiol Imaging [Internet]. 2017;27(3):342. Available from:
    1. Ketai L, Paul NS, Wong KT. Radiology of Severe Acute Respiratory Syndrome (SARS). J Thorac Imaging [Internet]. 2006;21(4):276‐283. Available from
    1. Hosseiny M, Kooraki S, Gholamrezanezhad A, Reddy S, Myers L. Radiology perspective of Coronavirus disease 2019 (COVID‐19): lessons from severe acute respiratory syndrome and middle east respiratory syndrome. Am J Roentgenol [Internet]. 2020;28:1‐5. Available from
    1. Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID‐19): a pictorial review. Eur Radiol [Internet]. 2020; Available from:
    1. Zhou S, Wang Y, Zhu T, Xia L. CT Features of Coronavirus disease 2019 (COVID‐19) pneumonia in 62 patients in Wuhan, China. Am J Roentgenol [Internet]. 2020;5:1‐8. Available from
    1. Ahmed LA, EL‐Maraghy SA, Rizk SM. Role of the KATP channel in the protective effect of nicorandil on cyclophosphamide‐induced lung and testicular toxicity in rats. Sci Rep [Internet]. 2015;5(1):14043. Available from:
    1. Patel S, Patel N, Patel V. Anti‐fibrotic potential of nicorandil in the treatment of bleomycin induced pulmonary fibrosis. J Young Pharm [Internet]. 2017;9(3):376‐380. Available from
    1. Kseibati MO, Shehatou GSG, Sharawy MH, Eladl AE, Salem HA. Nicorandil ameliorates bleomycin‐induced pulmonary fibrosis in rats through modulating eNOS, iNOS, TXNIP and HIF‐1α levels. Life Sci [Internet]. 2020;246:117423. Available from
    1. Kasama S, Toyama T, Sumino H, et al. Long‐term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction. J Nucl Med [Internet]. 2007;48(10):1676‐1682. Available from
    1. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost [Internet]. 2020;18(4):844‐847. Available from
    1. Mitchell WB. Thromboinflammation in COVID‐19 acute lung injury. Paediatric Respiratory Reviews. 2020. 10.1016/j.prrv.2020.06.004
    1. Gupta N, Zhao Y‐Y, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res [Internet]. 2019;181:77‐83. Available from
    1. Iba T, Levy JH, Warkentin TE, Thachil J, Poll T, Levi M. Diagnosis and management of sepsis‐induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost [Internet]. 2019;17(11):1989‐1994. Available from
    1. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost [Internet]. 2020. 10.1111/jth.14817
    1. DiNicolantonio JJ, McCarty M. Thrombotic complications of COVID‐19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endosomal NADPH oxidase. Open Hear [Internet]. 2020;7(1):e001337. Available from: .
    1. Green SJ. Covid‐19 accelerates endothelial dysfunction and nitric oxide deficiency. Microbes Infect [Internet]. 2020;22(4–5):149‐150. Available from .
    1. Isidori AM, Giannetta E, Pofi R, et al. Targeting the NO‐cGMP‐PDE5 pathway in COVID‐19 infection. The DEDALO project. Andrology [Internet]. 2020;andr.12837. Available from: 10.1111/andr.12837
    1. Åkerström S, Gunalan V, Keng CT, Tan Y‐J, Mirazimi A. Dual effect of nitric oxide on SARS‐CoV replication: Viral RNA production and palmitoylation of the S protein are affected. Virology [Internet]. 2009;395(1):1‐9. Available from .
    1. Martel J, Ko Y‐F, Young JD, Ojcius DM. Could nasal nitric oxide help to mitigate the severity of COVID‐19? Microbes Infect [Internet]. 2020;22(4–5):168‐171. Available from .
    1. Dharavath RN, Dutt M, Kumar S, Badyal P, Rawat N, Kaur T, et al.Repurposing of FDA approved drugs as COVID‐19 therapeutics: Safety concerns and contraindications of drugs in clinical trials [Internet]. 2020. p. preprint. Available from: . 10.20944/preprints202006.0232.v1
    1. Aizawa K, Takahari Y, Higashijima N, et al. Nicorandil prevents sirolimus‐induced production of reactive oxygen species, endothelial dysfunction, and thrombus formation. J Pharmacol Sci [Internet]. 2015;127(3):284‐291. Available from
    1. Sahara M, Sata M, Morita T, Hirata Y, Nagai R. Nicorandil Attenuates Monocrotaline‐Induced Vascular Endothelial Damage and Pulmonary Arterial Hypertension. Gaetano C, editor. PLoS One [Internet]. 2012;7(3):e33367. Available from: 10.1371/journal.pone.0033367
    1. Peng R, Yang X, Liang X. Nicorandil effects on platelet function, Hs‐CRP, MMP‐9 and myocardial antioxidation in patients with unstable angina. Exp Ther Med [Internet]. 2019;8(4):3095–3099.
    1. Lu L, Gao F, Liu Z‐C, Jing X‐W. Effect of adjuvant nicorandil therapy on inflammation, plaque stability and platelet function in patients with unstable angina. J Hainan Med Univ. 2017;23(2):92‐96.
    1. Zheng Y‐Y, Ma Y‐T, Zhang J‐Y, Xie X. COVID‐19 and the cardiovascular system. Nat Rev Cardiol [Internet]. 2020;17(5):259‐260. Available from:
    1. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with Coronavirus disease 2019 (COVID‐19). JAMA Cardiol [Internet]. 2020;5(7):819. Available from:
    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet [Internet]. 2020;395(10223):497‐506. Available from
    1. Xu X, Liu X, Yu L, Ma J, Yu S, Ni M. Impact of intracoronary nicorandil before stent deployment in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Exp Ther Med [Internet]. 2019;19(1):137–146.
    1. Sakata Y, Nakatani D, Shimizu M, et al. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction. J Cardiol [Internet]. 2012;59(1):14‐21. Available from: 10.1016/j.jjcc.2011.08.001
    1. Abdel‐Raheem IT, Taye A, Abouzied MM. Cardioprotective effects of nicorandil, a mitochondrial potassium channel opener against doxorubicin‐induced cardiotoxicity in rats. Basic Clin Pharmacol Toxicol [Internet]. 2013;113(3):158‐166. Available from 10.1111/bcpt.12078
    1. Liou J‐Y, Hong H‐J, Sung L‐C, et al. Nicorandil inhibits angiotensin‐II‐induced proliferation of cultured rat cardiac fibroblasts. Pharmacology [Internet]. 2011;87(3–4):144‐151. Available from
    1. Ishii H, Ichimiya S, Kanashiro M, Amano T, Matsubara T, Murohara T. Effects of intravenous nicorandil before reperfusion for acute myocardial infarction in patients with stress hyperglycemia. Diabetes Care [Internet]. 2006;29(2):202‐206. Available from
    1. Coltart DJ, Signy M. Acute hemodynamic effects of single‐dose nicorandil in coronary artery disease. Am J Cardiol [Internet]. 1989;63(21):J34‐J39. Available from
    1. Giles TD, Pina IL, Quiroz AC, et al. Hemodynamic and neurohumoral responses to intravenous nicorandil in congestive heart failure in humans. J Cardiovasc Pharmacol [Internet]. 1992;20(4):572‐578. Available from
    1. Tanaka K, Kato K, Takano T, et al. Acute effects of intravenous nicorandil on hemodynamics in patients hospitalized with acute decompensated heart failure. J Cardiol [Internet]. 2010;56(3):291‐299. Available from
    1. Minami Y, Nagashima M, Kajimoto K, Shiga T, Hagiwara N. Acute efficacy and safety of intravenous administration of nicorandil in patients with acute heart failure syndromes: usefulness of noninvasive echocardiographic hemodynamic evaluation. J Cardiovasc Pharmacol [Internet]. 2009;54(4):335‐340. Available from
    1. Shirakabe A, Hata N, Yokoyama S, et al. Efficacy and safety of nicorandil therapy in patients with acute heart failure. J Cardiol [Internet]. 2010;56(3):339‐347. Available from
    1. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid‐19. N Engl J Med [Internet]. 2020;382(25):e102. Available from:
    1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J [Internet]. 2016;37(27):2129‐2200. Available from
    1. Su H, Yang M, Wan C, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID‐19 in China. Kidney Int [Internet]. 2020;98(1):219‐227. Available from:
    1. Shiraishi T, Tamura Y, Taniguchi K, et al. Combination of ACE inhibitor with nicorandil provides further protection in chronic kidney disease. Am J Physiol Physiol [Internet]. 2014;307(12):F1313‐F1322. Available from
    1. Tamura Y, Tanabe K, Kitagawa W, et al. Nicorandil, a K atp channel opener, alleviates chronic renal injury by targeting podocytes and macrophages. Am J Physiol Physiol [Internet]. 2012;303(3):F339‐F349. Available from
    1. Tashiro Y, Yogo K, Serizawa K, Endo K. Nicorandil suppresses urinary protein excretion and activates eNOS in Dahl salt‐sensitive hypertensive rats. Clin Exp Nephrol [Internet]. 2015;19(3):343‐349. Available from
    1. Shimamoto Y, Kubo T, Tanabe K, et al. Effects of intravenous bolus injection of nicorandil on renal artery flow velocity assessed by color Doppler ultrasound. J Cardiol [Internet]. 2017;69(1):364‐368. Available from
    1. Ishii H, Toriyama T, Aoyama T, et al. Efficacy of oral nicorandil in patients with end‐stage renal disease: A retrospective chart review after coronary angioplasty in japanese patients receiving hemodialysis. Clin Ther [Internet]. 2007;29(1):110‐122. Available from

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir